944898-93-5 Usage
Uses
Used in Pharmaceutical Industry:
4-CYANO-3-IODO (1H)INDAZOLE is used as a key intermediate in the synthesis of new drugs and pharmaceuticals, contributing to the development of innovative treatments and therapies.
Used in Chemical Research:
4-CYANO-3-IODO (1H)INDAZOLE serves as a research reagent, facilitating the exploration and advancement of chemical research, particularly in the field of organic synthesis and medicinal chemistry.
Used in Material Development:
4-CYANO-3-IODO (1H)INDAZOLE may also have applications in the development of new materials, owing to its distinct structure and properties, which can be harnessed to create novel substances with unique characteristics.
Check Digit Verification of cas no
The CAS Registry Mumber 944898-93-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,4,8,9 and 8 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 944898-93:
(8*9)+(7*4)+(6*4)+(5*8)+(4*9)+(3*8)+(2*9)+(1*3)=245
245 % 10 = 5
So 944898-93-5 is a valid CAS Registry Number.
944898-93-5Relevant academic research and scientific papers
New CRTh2 antagonists.
-
Paragraph 0226, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
NEW CRTh2 ANTAGONISTS
-
Page/Page column 86, (2013/03/26)
The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.
SERINE/THREONINE PAK1 INHIBITORS
-
, (2013/03/26)
Compounds having the formula I wherein A, Z, R1a, R1b, R2, R3, R4, R5, R6, R7, R9, R10, Ra, Rb and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
